Andrographis para Upper Respiratory Tract Infections
B Evidencia Al menos un ensayo aleatorizado lo respalda, con resultados mayoritariamente consistentes.Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'immunecited.com';
const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Conclusión
Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
Key Study Findings
Randomized Controlled Trial
n=331
1.0 weeks
Double-blind
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …
Dose: 200 mg/day
vs: placebo
Outcome: URTI symptom severity
Efecto: None
p = 0.034
Población: Participants with uncomplicated URTI
Review
A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …
Dose: None
vs: None
Outcome: URTI symptom severity
Efecto: None
None
Población: COVID-19/URTI patients
Review
Plant-Based Support of Respiratory Health during Viral Outbreaks.
Dose: None
vs: None
Outcome: None
Efecto: None
None
Población: None
Other
n=179
Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.
Dose: 60 mg
vs: placebo
Outcome: None
Efecto: None
p = 0.0053
Población: None
Meta-Analysis
n=1000
Safety of Andrographis paniculata: A systematic review and meta-analysis.
Dose: 95%
vs: control
Outcome: None
Efecto: None
None
Población: upper respiratory tract infection
Other
In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.
Dose: 6 μg/mL
vs: Control group
Outcome: None
Efecto: None
None
Población: None
Key Statistics
7
Estudios
800
Participantes
↑
Positive
B
Calificación
Referenced Papers
Complementary therapies in …
2023
6 citas
Molecules (Basel, Switzerland)
2022
80 citas
Journal of agricultural …
2022
9 citas
Pharmacoepidemiology and drug …
2021
32 citas
Journal of traditional …
2021
9 citas
Brazilian journal of …
2020
45 citas
Cell death & …
2019
160 citas
Biomedicine & pharmacotherapy …
2019
103 citas
Phytomedicine : international …
2010
107 citas
Alternative medicine review …
2007
163 citas
American journal of …
2006
51 citas
Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy.
Systematic Review
Planta medica
2004
262 citas
Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials.
Systematic Review
Journal of clinical …
2004
157 citas
Primary care
2002
56 citas
Journal of the …
1990
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosificaciones de uso común
- acute:
- 400 mg 3x/day for up to 7 days
- general:
- 200 mg standardized extract (30% andrographolides) 2x/day
Límite superior: No established UL; short-term use (<14 days)
Dosificaciones estudiadas en la investigación
| Dosificación | Duración | Efecto | N |
|---|---|---|---|
| 200 mg/day | 1.0 weeks | Positive | 331 |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| 60 mg | -- | Positive | 179 |
| 95% | -- | Neutral | 1000 |
| 6 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| 18 G | 4.0 weeks | Mixed | -- |
Mejor momento para tomar: At first sign of symptoms; with meals
Safety & Side Effects
Efectos secundarios reportados
- ⚠ Gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Headache
- ⚠ Fatigue
- ⚠ Allergic reactions (rare)
- ⚠ Potential anti-fertility effects (high doses in animal studies)
Interacciones conocidas
- ● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
- ● Antihypertensive medications (additive blood pressure lowering)
- ● Immunosuppressant medications (may counteract immunosuppression)
Ingesta máxima tolerable: No established UL; short-term use (<14 days)
Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.
Frequently Asked Questions
Does Andrographis help with Upper Respiratory Tract Infections?
Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).
How much Andrographis should I take for Upper Respiratory Tract Infections?
Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Andrographis?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.
Related Evidence
Otros ingredientes para Upper Respiratory Tract Infections
References
- [1] Jeffrey Pradeep Raj et al.. Complement Ther Med. 2023. Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … doi:10.1016/j.ctim.2023.102934 PubMed
- [2] Aekkhaluck Intharuksa et al.. Molecules. 2022. A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. doi:10.3390/molecules27144479 PubMed
- [3] Thirumurugan Rathinasabapathy et al.. J Agric Food Chem. 2022. Plant-Based Support of Respiratory Health during Viral Outbreaks. doi:10.1021/acs.jafc.1c06227 PubMed
- [4] Wiwan Worakunphanich et al.. Pharmacoepidemiol Drug Saf. 2021. Safety of Andrographis paniculata: A systematic review and meta-analysis. doi:10.1002/pds.5190 PubMed
- [5] Mikayel Narimanyan et al.. J Tradit Complement Med. 2021. Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. doi:10.1016/j.jtcme.2021.06.001 PubMed
- [6] Moumita Majumdar et al.. Braz J Microbiol. 2020. In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. doi:10.1007/s42770-019-00169-0 PubMed
- [7] Jian Gao et al.. Cell Death Dis. 2019. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. doi:10.1038/s41419-019-2195-8 PubMed
- [8] Jiashu Lu et al.. Biomed Pharmacother. 2019. A review for the neuroprotective effects of andrographolide in the central nervous system. doi:10.1016/j.biopha.2019.109078 PubMed
- [9] R C Saxena et al.. Phytomedicine. 2010. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … doi:10.1016/j.phymed.2009.12.001 PubMed
- [10] Mario Roxas et al.. Altern Med Rev. 2007. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. PubMed
- [11] Roxane R Carr et al.. Am J Health Syst Pharm. 2006. Complementary and alternative medicine for upper-respiratory-tract infection in children. doi:10.2146/ajhp040613 PubMed
- [12] Joanna Thompson Coon et al.. Planta Med. 2004. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. doi:10.1055/s-2004-818938 PubMed
- [13] N Poolsup et al.. J Clin Pharm Ther. 2004. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. doi:10.1046/j.1365-2710.2003.00534.x PubMed
- [14] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
- [15] A Leelarasamee et al.. J Med Assoc Thai. 1990. Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. PubMed
Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.